NeoPharm, Inc. is a biopharmaceutical Delaware corporation incorporated on June 15, 1990. NeoPharm, Inc. is engaged in the research, development, and commercialization of drugs for the treatment of cancer. The Company has built the drug development program around its two proprietary technology platforms: a tumor-targeting toxin platform and NeoLipid liposomal drug delivery system.

Acquired Companies: Insys Therapeutics, Inc.